Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion.

OBJECTIVES To evaluate the effects and safety of intravitreal injections of autologous plasmin enzyme (APE), without vitrectomy, as a treatment for macular edema secondary to branch retinal vein occlusion. DESIGN Prospective, comparative, interventional case series. METHODS Patients were recruited and enrolled consecutively from February 1 through October 31, 2008, at the Retina Unit of the Hospital General Universitario, Valencia, Spain. An eye from 8 patients diagnosed as having macular edema due to branch retinal vein occlusion received an injection, after having received topical anesthesia, of 0.2 mL of APE, which had been obtained using a simplified method. Best-corrected visual acuity and central macular thickness measured by optical coherence tomography constitute the main outcome measures of the study. RESULTS The mean (SD) central macular thickness decreased from 494.875 (68.82) to 226.375 (28.67) μm 1 month after APE injection and to 228.570 (21.53) μm after 6 months (P < .001). The best-corrected visual acuity (logarithm of the minimal angle of resolution) improved from a preoperative value of 0.552 (0.17) to 0.217 (0.087) (mean, 20/80-20/32, Snellen equivalent) at the end of follow-up (P < .01). No secondary effects were observed during 6 months of follow-up. CONCLUSION This pilot study suggests that intravitreal injection of APE as a treatment for macular edema secondary to branch retinal vein occlusion improves central macular thickness and best-corrected visual acuity and may be a safe and effective alternative therapy for this condition if confirmed in controlled trials compared with standard care with longer follow-up.

[1]  Ingrid U Scott,et al.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. , 2009, Archives of ophthalmology.

[2]  M. Díaz-Llopis,et al.  Plasmina autóloga intravítrea sin asociar vitrectomía: Vitreolisis farmacológica, método perfeccionado con uroquinasa , 2008 .

[3]  F. J. Romero,et al.  [Intravitreal autologous plasmin without associated-vitrectomy. Pharmacological vitreolysis, a perfeccionated method using urokinase]. , 2008, Archivos de la Sociedad Espanola de Oftalmologia.

[4]  M. Díaz-Llopis,et al.  Vitrectomía enzimática por inyección intravítrea de plasmina autóloga como tratamiento inicial del edema macular diabético difuso , 2008 .

[5]  Matus Rehak,et al.  Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment Modalities , 2008, Current eye research.

[6]  M. Díaz-Llopis,et al.  [Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema]. , 2008, Archivos de la Sociedad Espanola de Oftalmologia.

[7]  N. Yoshimura,et al.  ROLE OF POSTERIOR VITREOUS DETACHMENT INDUCED BY INTRAVITREAL TISSUE PLASMINOGEN ACTIVATOR IN MACULAR EDEMA WITH CENTRAL RETINAL VEIN OCCLUSION , 2007, Retina.

[8]  R. Avery,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION , 2007, Retina.

[9]  F. Adatia,et al.  Surgical macular decompression for macular edema in retinal vein occlusion. , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[10]  J. Larsson,et al.  Vitrectomy for non-ischaemic macular oedema in retinal vein occlusion. , 2006, Acta ophthalmologica Scandinavica.

[11]  S. Rizzo,et al.  AUTOLOGOUS PLASMIN FOR PHARMACOLOGIC VITREOLYSIS PREPARED 1 HOUR BEFORE SURGERY , 2006, Retina.

[12]  K. Erkiliç,et al.  Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion , 2006, Eye.

[13]  Michael D. Ober,et al.  INTRAVITREAL TRIAMCINOLONE INJECTION FOR TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION , 2005, Retina.

[14]  R. Feist,et al.  Sheathotomy to decompress branch retinal vein occlusion: a matched control study. , 2004, Ophthalmology.

[15]  C. Pournaras,et al.  Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[16]  George A. Williams,et al.  Autologous plasmin enzyme in the surgical management of diabetic retinopathy. , 2001, Ophthalmology.

[17]  S. Saika,et al.  Surgical posterior vitreous detachment combined with gas/air tamponade for treating macular edema associated with branch retinal vein occlusion: retinal tomography and visual outcome , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[18]  A. Kampik,et al.  Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy , 2001, The British journal of ophthalmology.

[19]  T. Katano,et al.  Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. , 1999, American journal of ophthalmology.

[20]  George A. Williams,et al.  Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. , 1998, Ophthalmology.

[21]  J. Sebag Pharmacologic vitreolysis. , 1998, Retina.

[22]  T. Hikichi,et al.  Role of the vitreous and macular edema in branch retinal vein occlusion. , 1997, Ophthalmic surgery and lasers.

[23]  S D Miller,et al.  Argon laser photocoagulation for macular edema in branch vein occlusion. , 1985, American journal of ophthalmology.

[24]  Gutman Fa Macular edema in branch retinal vein occlusion: prognosis and management. , 1977 .